Dr. Sagar Lonial on Early Treatment Versus Observation for Smoldering Multiple Myeloma

Sagar Lonial, MD
Published: Friday, Mar 18, 2016



Sagar Lonial, MD, professor and chair, department of Hematology & Medical Oncology, Emory University School of Medicine, Chief Medical Officer, Winship Cancer Institute of Emory University, discusses treatment for smoldering multiple myeloma.

One of the biggest questions regarding smoldering multiple myeloma is whether or not patients with it require early treatment or simply observation. Lonial believes patients who are classified as having high-risk smoldering who need earlier treatment, should be reclassified as having standard multiple myeloma.

There may be non-high-risk patients that require treatment as well, says Lonial. There are small studies that are investigating this, but currently there is no evidence that patients with true smoldering should be treated earlier.

<<< View more from the 2016 Congress on Hematologic Malignancies



Sagar Lonial, MD, professor and chair, department of Hematology & Medical Oncology, Emory University School of Medicine, Chief Medical Officer, Winship Cancer Institute of Emory University, discusses treatment for smoldering multiple myeloma.

One of the biggest questions regarding smoldering multiple myeloma is whether or not patients with it require early treatment or simply observation. Lonial believes patients who are classified as having high-risk smoldering who need earlier treatment, should be reclassified as having standard multiple myeloma.

There may be non-high-risk patients that require treatment as well, says Lonial. There are small studies that are investigating this, but currently there is no evidence that patients with true smoldering should be treated earlier.

<<< View more from the 2016 Congress on Hematologic Malignancies


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x